HumacyteHUMA
HUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Employees: 185
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
112% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 25
29% more capital invested
Capital invested by funds: $151M [Q2] → $195M (+$43.7M) [Q3]
15% more funds holding
Funds holding: 123 [Q2] → 141 (+18) [Q3]
3.57% more ownership
Funds ownership: 26.42% [Q2] → 29.98% (+3.57%) [Q3]
62% less call options, than puts
Call options by funds: $2.01M | Put options by funds: $5.27M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
240%
upside
Avg. target
$21
365%
upside
High target
$25
467%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 39% 1-year accuracy 74 / 190 met price target | 467%upside $25 | Buy Maintained | 13 Jan 2025 |
Benchmark Bruce Jackson 36% 1-year accuracy 19 / 53 met price target | 285%upside $17 | Buy Maintained | 23 Dec 2024 |
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 22 / 59 met price target | 240%upside $15 | Buy Reiterated | 20 Dec 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 74 / 190 met price target | 467%upside $25 | Buy Maintained | 28 Oct 2024 |
Financial journalist opinion
Based on 253 articles about HUMA published over the past 30 days
Neutral
Accesswire
3 days ago
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123538&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Business Wire
3 days ago
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Neutral
Accesswire
3 days ago
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123437&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
3 days ago
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline.
Neutral
Business Wire
3 days ago
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-36.
Neutral
GlobeNewsWire
3 days ago
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options
Neutral
Accesswire
3 days ago
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/humacyte-inc-lawsuit-submission-form?prid=123415&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 days ago
DEADLINE TODAY: The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Humacyte, Inc.
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
Neutral
Accesswire
3 days ago
FINAL REMINDER HUMA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Humacyte, Inc. Investors to Participate in the Class Action Lawsuit
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024 inclusive (the "Class Period").
Neutral
PRNewsWire
3 days ago
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMA
NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024.
Charts implemented using Lightweight Charts™